Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
B.S. in Accountancy from University of Illinois at Urbana Champaign
Ernst and Young Financial Services Office Assurance
January 2012 - present
New York, NY
I am a small retail investor. I do not short stocks. There are certain equities I cannot own because it would be a violation of the Ernst and Young LLP independence policy. I do not own any shares of Ernst and Young LLP clients.
I have worked in market research at Proctor and Gamble, and as a systems analyst at AT &T. I have also worked in healthcare, and run a successful internet adventure in addition to being a known indie rock musician. I lost pretty much everything when my business burned 10 plus years ago (underinsured). Illness nearly took me just two years ago, but I am a survivor, and back 100%. During those lean ten years I day traded high risk high dividend stocks and managed to come out with enough to retire. Don't want to do that again. Time to invest for income.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.
I live in Southern California and work in the finance industry. BDCs are a special outside of work interest of mine and I have begun a blog to document my research. I always welcome questions/comments/discussions.
PropThink is an intelligence service that delivers long and short trading ideas to investors in the healthcare and life sciences sectors. Our Editorial Team is comprised of individuals with a strong background in science, medicine and the business of successfully commercializing therapeutics, medical devices, diagnostics and healthcare services. Our ultimate objective is to leverage the knowledge, experience, and relationships of our contributors to introduce our subscribers to profitable long and short investment opportunities in the healthcare sector.
Successfully trading, and investing in emerging growth healthcare companies is a difficult task. Over 90% of drugs never make it out of the clinic. Huge capital requirements along the way result in highly dilutive equity financings often done on the backs of retail investors. At PropThink, we believe that due diligence is the key to success in this industry. We leverage a combined 50 years of experience in science, medicine, legal, regulatory affairs, finance, and operational industry experience to analyze companies at a highly technical level. This detailed analysis and due diligence process defines our editorial strategy and provides our subscribers a high level of confidence in our research. Our focus is on identifying and analyzing technically-complicated companies and equities that are grossly over or under-valued.
Visit PropThink.com to see all of our coverage and research, and subscribe to our free newsletter to receive reports, articles, and trading alerts.
MarketScanners is a newsletter featuring Market Scans and Trading Ideas based on many different types of fundamentals scans, market analytics and technical analysis. Coupled with fundamentals and news catalysts, some of the plays we highlight for investors tend to move quickly and make great candidates for momentum traders and others seeking quick picks based on solid analysis and research.
Some companies featured in our newsletter pay MarketScanners for research, analysis, articles and distribution. Our reports contain forward-looking statements relating to the developments of the featured company’s products, services, future operating results and the future of the market. Statements contained in writing or in interviews are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected.
Since we are often compensated in shares or cash for our services, investors should evaluate the information on the Site with that in mind and should always perform their own independent analysis.
I have been an investor in several stock exchanges around the globe for the last 16 years. My trading philosophy is to be ahead of the curve of demand. I strongly believe that diligence and patience are fundamental to stock market success.
I attained my MBA from the Keio Business School and have worked in the field of international business consulting for the last 12 years. My job has allowed me to travel the world, which gives me great joy, as it combines my two passions, to visit new places and finance.
We are a group of Harvard Medical School students who met at the Harvard Biotechnology Club in 2011, and got interested in analyzing and investing in biotech stocks. We hope to use our biomedical expertise to deconstruct the complex technologies underlying these biotech companies and their competitors, and identify long-term investment opportunities for ourselves and others.
I began investing at the age of 14 and, at the age of 21, secured a job as a financial consultant at a top Wall Street firm. At 23, I was managing $65 million in client funds. Ultimately frustrated by Wall Street's prevalent practice of contradictory buy-side/sell-side analysis and behavior, I obtained my MBA from a top business school and became a proprietary trader contributing to a successful firm.
Having studied options trading, finance theories, efficient markets and economics, I learned that although not worthless, formal education was ultimately irrelevant to peak performance in real-world market application. Upon achieving consistent above-market returns, I started my own fund just 1 day before the market peak in October, 2007. Now I look to share ideas with the investing/trading community to help offset the toxic practices so prevalent on Wall Street.
Kapitall is the online finance platform for the next generation, where investing is as easy as drag, drop and trade. With an intuitive and playful user experience, Kapitall offers tools that make it easy to build virtual and real brokerage portfolios, share ideas and research stocks and funds.
It is very hard or impossible to time the broad market consistently — there are no famous investors that got rich by consistently knowing what the broad market would do next. This only makes sense, as there are just too many variables in the broad market. But there are many famous investors who got rich analyzing individual securities, and this is where you should put your focus. You can get an edge in individual securities. Joe Springer was the number 1 ranked stock analyst in the world by tipranks.com, and on most days is still ranked in the top 5%. Joe is a Certified Technical Trainer, and enjoys teaching about the stock market as well as managing portfolios. If you would like to follow Joe on Twitter, his handle is @JoeSpringer.
I am a mid-westerner and computer science grad helping to launch a start-up medical service company. I've worked on medical intake including XML delivery, medical instrumentation imaging, tissue ablation micro-imaging and MEMs device modeling.
I know biotech, which I prefer to call biopharmaceuticals. Period. I love investing and I write when I can!
For the past 30 years, I have been involved in startups, as a founder, and active investor. My first company was purchased by Johnson & Johnson, which set the foundation for future investments.
My level of trading escalated after graduating from college, primarily as a result of my relationship with the founder of the Silicon Valley venture capital firm, Institutional Venture Partners, (Netflix, Twitter, Oracle). By focusing on VC backed companies, I soon learned the advantage of investing in promising companies before they became household names. My interest in startups has never waned, and has become my primary focus today.
Mike Havrilla is a former pharmacist (retail and home infusion settings), biotech stock trader, and writer with experience that includes full-time online trading since 2009, working as a full-time pharmacist from 2004-2009, and writing for investors since 2007. Mike holds Doctor of Pharmacy (PharmD) and Bachelor of Science (Biology) degrees from the University of Pittsburgh and worked in the pharmaceutical industry for Wyeth prior to pharmacy school. He is also an avid runner and has completed over 20 marathons with a personal best time under three hours for the 26.2 mile race and under 80 minutes for the half marathon. Mike merged his former publishing business with BioRunUp.com / Mark Messier in October 2010, creating a new online biotech stock research and trading subscription service.
Alan Brochstein, CFA, was the first investment professional to devote himself to sharing his observations about the cannabis industry from an investor's perspective publicly. He runs 420 Investor, a subscription-based due diligence platform for investors interested in the publicly-traded cannabis stocks and is also the founder of New Cannabis Ventures, a content aggregation site focused on investors and entrepreneurs in the cannabis industry.
Alan has worked in the securities industry since 1986, primarily with the responsibility for managing investments in institutional environments until he founded AB Analytical Services in 2007 in order to provide independent research and consulting to registered investment advisors. In addition to advising several different hedge funds and investment managers, including Friedberg Investment Management, where he participated as a member of its investment management committee, Alan was also a senior analyst for the independent research firm Management CV. In 2008, he began providing a first-of-its-kind subscription-based service for individual investors, Invest By Model, which offered two different portfolios that investors could replicate in their own accounts for $20 per month. Alan also offered The Analytical Trader at Marketfy, where he used fundamental and technical analysis in a disciplined process to offer specific trade ideas geared towards swing traders.
Alan launched www.420Investor.com in late 2013 as the premier source of information for "Green Rush" investors seeking to capitalize on the proliferation of legalized medical and recreational cannabis. In March 2014, Alan, who is a member of the National Cannabis Industry Association, began to focus solely on the cannabis sector. He launched www.NewCannabisVentures.com in late 2015.
You can follow Alan on Facebook (www.facebook.com/420investor) or on Twitter (https://twitter.com/Invest420). Alan also moderates a large LinkedIn group focused on the cannabis industry, Cannabis Investors & Entrepreneurs (https://www.linkedin.com/groups/6523904)
DISCLAIMER: Each article or comment written by this author is intended as general information only, and is not intended to provide specific advice, or due diligence to be relied on. As such, the information presented in any article or comment does not consider any reader’s personal investment objectives or financial situation; therefore, no articles or comments make investment recommendations. The opinions expressed in any articles or comments on this website are my own and do not necessarily reflect the views or opinions of any third party. I am not responsible for actions taken, or not taken based the content of this site.
Investment strategies or securities mentioned in any article may not be suitable for all investors. The risk of loss in trading securities, including options, and futures can be substantial. Options involve risk and are not suitable for all investors. Please understand all risks associated with investing before investing. Prior to buying or selling an option, a person should read a copy of Characteristics and Risks of Standardized Options (http://www.optionsclearing.com/about/publications/character-risks.jsp). Options or other transactions could involve complex tax considerations that should be carefully reviewed and considered along with each reader’s personal financial situation and all other relevant risk factors prior to entering into any transaction. Probability analysis results are theoretical and in nature, and do not reflect any degree of certainty of an event occurring or not occurring.
While I believe the information provided in any article or comment is reliable; however, I do not guarantee its accuracy, timelines, or completeness. Financial information changes daily and articles and comments are not updated for subsequent changes in financial position or share prices. Transaction costs (commissions and fees) should be considered before entering trades and not accounted for in analyses presented.
Past performance referenced in any article or comment is not a guarantee of future performance. You should always consider the risks of investing in the light of your personal circumstances and your due diligence should include consulting with your professional advisor.
Links to and from websites do not imply any content endorsements. I am not responsible for, nor do I control the content of linked websites which are subject to change without my knowledge or consent.
I graudated summa cum laude with a M.S (Accounting & Information Analysis) and a B.S. (Finance & Accounting). I have over four years of financial markets experience. I actively follow equities with a focus on technology, high yield, and value stocks. In addition, I focus on conservative option strategies such as covered calls and cash secured puts to generate additional income in an effort to outperform the market.
Rich Steffens has grown up in New Jersey, is a successful businessman, and follows social media trends amongst life science and biotech companies. His family is deeply influenced by the ill effects of diabetes, and is a kidney donor to his older sister. His area of interests also includes cancer immunotherapy, which he started writing about in 2008. Rich jokes that he is one of the world's slowest marathon runners, and he runs with MSKCCs Fred's Team to support cancer research, raising over $20,000 in ten years to support MSKCCs efforts.
Rich states- I am not qualified to offer investment or medical advice, and make no claims that I am an expert in these areas. I seek to share and learn.
I am an individual investor. I am here to share the information on Stocks - Biotechnology, Information Technology, Consumer, Retail, Finance, Energy and wherever we can make money ;-)
Nicholas Smith is currently a financial analyst for Yahoo. He graduated from Creighton University with majors in finance and accounting. He has over three years of experience working as an analyst in a variety of fields, including investment research, corporate FP&A and private equity. His three years working as an analyst combined with the experience he has obtained trading stocks over the past five years have provided him with a unique perspective on the financial markets.
I hold BS degrees in Biology and Environmental Policy in addition to an M.Ed in Science Education. I have experience as a researcher in the biotech sector. Currently, I teach Biology courses as well as publish articles and research in the fields of science, education and public policy.
GuruFundPicks.com offers top buy & sell picks based on the collective or Consensus Picks' of over 330 of our hand-picked top hedge & mutual fund managers, incl. 78 legendary or guru fund managers, 27 of the world's largest or mega funds, 165 sector-focused funds (in gold, biotech, tech, energy, consumer, finance & REITs), 59 billionaires, 54 new masters and 40 tiger, 52 shareholder activist and our Winners Circle Top 100 Performing Hedge Fund Managers (updated quarterly). We offer market-beating tools and services including Consensus Picks' DIY Tools, Top 20 Small-Cap and Top 30 All-Cap Long/Short Newsletters based on the Consensus Picks system, and Trade Alert Services for Self & Auto-Trading. All of our services have beaten market averages by wide margins. See our website GuruFundPicks.com for the latest performance numbers, or contact us at support@GuruFundPicks.com.
The two authors are co-managers of a family partnership long/short equity fund since 2001, that have a successful track record in trading primarily small-cap aggressive growth companies based on a fundamental valuation analysis of current news, including quarter reports, guidance, biotech clinical study results and other news. The junior partner is a self-taught private investor with a Business degree from the New York University's Leonard N. Stern School of Business and the senior partner has an MBA from the University of Virginia Darden School of Business, including prior MS & BS (Engg.) degrees, and with experience in business strategy consulting to large fortune 100 companies.
We are generally sector and market-cap agnostic, identifying opportunities using a 'stock picking' bottom-up, fundamentals-based, valuation-driven approach. However, we find most opportunities in the small-cap space, in technology & healthcare sectors, with some also found often in the consumer, energy & basic materials sectors.
Follow us on Seeking Alpha and Twitter (@GuruFundPicks), and connect with us on LinkedIn (http://www.linkedin.com/in/manishbabla)
M.E. Garza is one of the founders of the biotech and healthcare sector news portal BioMedReports.com. He believes in getting the news from credible sources on the street and often reaches out to CEOs and newsmakers directly for interviews and discussions about their companies. Since he began publishing in 2008, Garza has built a reputation as a writer and reporter who can move markets. His track record for accurately reporting rumors and alerting readers about developments in the biotech/healthcare sector is unmatched during that time.
I am a small-time writer/blogger who dreams big and enjoys researching and writing about biotechs and pharmaceuticals. My work experiences include food safety, water quality, pesticides, food additives, paints, plastics and pharmaceutical precursors. My focus as of late has been researching the treatment options for many cancers and prevention of their recurrence. Additional recent research has been in the stem cell field, an exciting field in its infancy but now becoming a teenager! My ongoing goal for investors is attempting to find under-the-radar or oversold pharmaceuticals or biotechs for investment potential.
I am currently employed by a Fortune 20 company, on any given day I am assessing risk management and the financial health of various companies. My time is spent looking at charts and numbers all day and I specialize in statistical analysis. I use the writers of various finance sites for my investing ideas, then do my own research prior to investing.
Thanks to those of you that have given me feedback and responded to my messages. I have found the writers at Seeking Alpha to be very accommodating and informative.
Dana Blankenhorn http://www.danablankenhorn.com has been a business journalist since 1978, and a futurist all his life.He warned about the coming Houston oil collapse in 1979. He began making a living on the Internet in 1985. He launched the first e-commerce daily for CMP in 1994, warned of the coming dot-bomb at a-clue.com in 1997 and began covering the Internet of Things in 2003.Along the way he's written for a host of newspapers, magazines, news services and Web sites. Most recently he was at TheStreet.com, covering technology and investments. He still has time for freelance assignments. He lives in Atlanta.
As an avid stock trader I am always searching for new opportunities. I utilize a very research heavy approach in my strategy that has done quite well for me over the years. I have earned a degree in Physics and an MBA in Finance. Although my educational background is an unconventional pairing, both have served me well. I am currently a consultant that specializes in small business development.